Back to search

Article

Gene therapy targeting the blood-brain barrier improves neurological symptoms in a model of genetic MCT8 deficiency

2021-12-09

Abstract excerpt

The solute carrier monocarboxylate transporter 8 (MCT8) transports the thyroid hormones thyroxine and tri-iodothyronine (T3) across cell membranes. MCT8 gene deficiency, termed Allan-Herndon-Dudley syndrome, is an important cause of X-linked intellectual and motor disability. As no treatment of the neurological symptoms is available yet, we tested a gene replacement therapy in Mct8 - and Oatp1c1 -deficient mice...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
1b3254b5-191f-5ad2-8cd4-a93091b18b21
DOI
10.1101/2021.12.05.471343
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Gene therapy targeting the blood-brain barrier improves neurological symptoms in a model of genetic MCT8 deficiencyDOI 10.1101/2021.12.05.471343
Select a neighboring publication to make it the new centre.